Evidence map›Paper›PMID 28424871›Full record

Trial reportInternational journal of colorectal disease2017

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.

Fernando Rivera, Meinolf Karthaus, J Randolph Hecht, Isabel Sevilla, Frédéric Forget, Gianpiero Fasola, Jean-Luc Canon, Xuesong Guan, Gaston Demonty, Lee S Schwartzberg

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of colorectal disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00819780 (A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer), which is not on this map. Cited by 69 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 9 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00819780 phase2completednot on this map

A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer

TypeinterventionalSponsorAmgenRan2009 to 2016Enrolled285ConditionsColon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal CancerArmsPanitumumab, Bevacizumab, mFOLFOX6
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 9 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Targeted therapy in advancedBMJ (Clinical research ed.) · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 6 countries.

Fernando RiveraHospital Universitario Marqués de Valdecilla, Av. de Valdecilla, 39008, Santander, Spain. oncrhf@humv.es.
Meinolf KarthausStädtisches Klinikum München, Klinikum Neuperlach, Munich, Germany.
J Randolph HechtDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Isabel SevillaVirgen de la Victoria University Hospital, Malaga, Spain.
Frédéric ForgetCentre Hospitalier de l'Ardenne, Libramont, Belgium.
Gianpiero FasolaUniversity Hospital Santa Maria della Misericordia, Udine, Italy.
Jean-Luc CanonGrand Hôpital de Charleroi, Charleroi, Belgium.
Xuesong GuanAmgen Inc., Biostatistics, Thousand Oaks, CA, USA.
Gaston DemontyMedical Development - Oncology, Amgen (Europe) GmbH, Zug, Switzerland.
Lee S SchwartzbergWest Clinic, Memphis, TN, USA.
Amgen (Switzerland) · CHAmgen (United States) · USCampbell Clinic · USGrand Charleroi Hospital · BEHospital Clínico Universitario Virgen de la Victoria · ESMarqués de Valdecilla University Hospital · ESMünchen Klinik Neuperlach · DEOspedale Santa Maria della Misericordia di Udine · ITUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report planned final overall (OS) and progression-free survival (PFS) analyses from the phase II PEAK trial (NCT00819780).

methodsPatients with previously untreated, KRAS exon 2 wild-type (WT) metastatic colorectal cancer (mCRC) were randomised to mFOLFOX6 plus panitumumab or bevacizumab. The primary endpoint was PFS; secondary endpoints included OS, objective response rate, duration of response (DoR), time to response, resection and safety. Treatment effect by tumour RAS status was a prespecified objective. Exploratory analyses included early tumour shrinkage (ETS) and depth of response (DpR).

resultsOne hundred seventy patients had RAS WT and 156 had RAS WT/BRAF WT mCRC. Median PFS was longer for panitumumab versus bevacizumab in the RAS WT (12.8 vs 10.1 months; hazard ratio (HR) = 0.68 [95% confidence intervals (CI) = 0.48-0.96]; p = 0.029) and RAS WT/BRAF WT (13.1 vs 10.1 months; HR = 0.61 [95% CI = 0.42-0.88]; p = 0.0075) populations. Median OS (68% OS events) for panitumumab versus bevacizumab was 36.9 versus 28.9 months (HR = 0.76 [95% CI = 0.53-1.11]; p = 0.15) and 41.3 versus 28.9 months (HR = 0.70 [95% CI = 0.48-1.04]; p = 0.08), in the RAS WT and RAS WT/BRAF WT populations, respectively. Median DoR (11.4 vs 9.0 months; HR = 0.59 [95% CI = 0.39-0.88]; p = 0.011) and DpR (65.0 vs 46.3%; p = 0.0018) were improved in the panitumumab group. More panitumumab patients experienced ≥30% ETS at week 8 (64 vs 45%; p = 0.052); ETS was associated with improved PFS/OS. No new safety signals occurred.

conclusionsFirst-line panitumumab + mFOLFOX6 increases PFS versus bevacizumab + mFOLFOX6 in patients with RAS WT mCRC.

Indexed as

AdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDemographyDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPanitumumabSurvival AnalysisAntibodies, MonoclonalBevacizumabPanitumumabBevacizumabFirst-lineMetastatic colorectal cancerOverall survivalPanitumumab

Identifiers

PMID28424871
PMCPMC5522523
OpenAlexW2606920054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.